Tiger Brokers

Rapid Micro Biosystems Publishes Investor Presentation on Growth Direct Microbial QC Automation Strategy

Reuters
Mar 03
<a href="https://laohu8.com/S/RPID">Rapid Micro Biosystems</a> Publishes Investor Presentation on Growth Direct Microbial QC Automation <a href="https://laohu8.com/S/MSTR">Strategy</a>

Rapid Micro Biosystems Inc. presented an update at the TD Cowen 46th Annual Health Care Conference, highlighting preliminary 2025 revenue of $33.6 million, including $17.8 million in recurring revenue. The company reported 190 cumulative Growth Direct system placements and 155 cumulative validations, with 28 systems placed and 18 validated in 2025, and noted that 75% of the top 20 global pharma companies by revenue are customers. The presentation also outlined a five-year co-exclusive distribution and collaboration agreement with Merck KGaA’s life science business, MilliporeSigma, covering sales of Growth Direct systems and consumables, a minimum purchase commitment in the first two years, and collaboration on supply efficiencies and joint product and technology innovation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapid Micro Biosystems Inc. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10